{"id":745506,"date":"2017-08-17T14:36:00","date_gmt":"2017-08-17T14:36:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/"},"modified":"2025-11-07T01:26:20","modified_gmt":"2025-11-07T06:26:20","slug":"lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/","title":{"rendered":"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       LYNPARZA\u2019s New Tablet Formulation Approved as Maintenance Treatment        for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of        BRCA-Mutation Status     <\/p>\n<p class=\"bwalignc\">       LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond        the Third-Line Setting     <\/p>\n<p class=\"bwalignc\">       Newly-Approved Tablet Formulation Means Improved Patient Convenience     <\/p>\n<p>\n      AstraZeneca and Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the<br \/>\n      United States and Canada, today announced that the U.S. Food and Drug<br \/>\n      Administration (FDA) has granted approval for the PARP inhibitor,<br \/>\n      LYNPARZA (olaparib), as follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        New use of LYNPARZA as a maintenance treatment for recurrent,<br \/>\n        epithelial ovarian, fallopian tube or primary peritoneal adult cancer<br \/>\n        who are in response to platinum-based chemotherapy, regardless of BRCA<br \/>\n        status;\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        New use of LYNPARZA tablets (2 tablets twice daily) as opposed to<br \/>\n        capsules (8 capsules twice daily);\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        LYNPARZA tablets also now indicated (conversion from the current<br \/>\n        accelerated approval) for the use in patients with deleterious or<br \/>\n        suspected deleterious germline BRCA-mutated advanced ovarian cancer,<br \/>\n        who have been treated with three or more prior lines of chemotherapy.\n      <\/li>\n<\/ul>\n<p>\n      Sean Bohen, executive vice president, global medicines development and<br \/>\n      chief medical officer of AstraZeneca, said: \u201cPhysicians have almost<br \/>\n      three years of clinical experience with LYNPARZA on the market and we<br \/>\n      are now pleased to bring this important medicine, in a new tablet<br \/>\n      formulation, to a broader group of women. Today\u2019s approvals validate<br \/>\n      more than 10 years of dedicated research behind LYNPARZA, the world\u2019s<br \/>\n      first PARP inhibitor, which now provides oncologists with the greater<br \/>\n      flexibility for use in terms of treatment settings. It builds on our<br \/>\n      recently-announced collaboration with Merck, which aims to further<br \/>\n      increase the number of treatment options available to patients.\u201d\n    <\/p>\n<p>\n      Eric Pujade-Lauraine, head of the women cancers and clinical research<br \/>\n      department at H\u00f4pitaux Universitaires Paris Centre, site H\u00f4tel-Dieu,<br \/>\n      AP-HP and principal investigator of the SOLO-2 trial, one of the trials<br \/>\n      supporting the approval, said: \u201cToday\u2019s approval is welcome news for<br \/>\n      U.S. patients with ovarian cancer, who are now able to benefit from<br \/>\n      treatment with olaparib irrespective of their BRCA-mutation status. This<br \/>\n      latest regulatory milestone underscores the breadth and depth of<br \/>\n      clinical data on olaparib, and not only demonstrates its efficacy as<br \/>\n      maintenance therapy, but adds to the data presented earlier this year<br \/>\n      showing sustained quality of life for patients undergoing treatment for<br \/>\n      this serious disease.\u201d\n    <\/p>\n<p>\n      Roger M. Perlmutter, president of Merck Research Laboratories, said: \u201cWe<br \/>\n      congratulate AstraZeneca on the approval of these new indications and<br \/>\n      the new dosage form and schedule for LYNPARZA, an important therapeutic<br \/>\n      advance for many patients with ovarian cancer. This is a significant<br \/>\n      first regulatory event in our collaboration with AstraZeneca. We look<br \/>\n      forward to working with AstraZeneca in our global collaboration to bring<br \/>\n      this medicine with its new indications to patients.\u201d\n    <\/p>\n<p>\n      Two randomized trials supported the new approvals and the conversion of<br \/>\n      accelerated approval to full approval which was originally based on a<br \/>\n      single-arm trial:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        SOLO-2 (n=295) confirmed the benefit of LYNPARZA in germline<br \/>\n        BRCA-mutated (gBRCAm) patients, demonstrating a 70% reduced risk of<br \/>\n        disease progression or death (HR 0.30 [95% CI, 0.22-0.41], P&lt;0.0001)<br \/>\n        and improved progression-free survival (PFS) to 19.1 vs 5.5 months for<br \/>\n        placebo by investigator-assessed analysis.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Study 19 (n=265) showed that LYNPARZA reduced the risk of disease<br \/>\n        progression or death by 65% and improved PFS compared with placebo in<br \/>\n        patients of any BRCA status (HR 0.35 [95% CI, 0.25-0.49], P&lt;0.0001;<br \/>\n        median PFS of 8.4 months vs 4.8 months for placebo). Additionally,<br \/>\n        patients in Study 19, treated with LYNPARZA as a maintenance therapy,<br \/>\n        had a median overall survival (OS) of 29.8 months vs 27.8 months for<br \/>\n        placebo (HR 0.73 [95% CI, 0.55-0.95]).\n      <\/li>\n<\/ul>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"12\">\n<p class=\"bwcellpmargin\">\n            Table 1.&nbsp;Summary of key efficacy results from randomized trials:\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"4\">\n          Analysis\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Reduction in the risk of<br \/>disease progression or death<br \/>(PFS)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            Reduction in the risk of<br \/>death (OS)\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            SOLO-2<br \/>[gBRCAm]\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <i>LYNPARZA<\/i>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            70% (HR 0.30 [95% CI, 0.22-<br \/>0.41], P&lt;0.0001)\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n          Data not yet mature\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          Placebo\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            Study 19<br \/>[PSR OC*]\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <i>LYNPARZA<\/i>\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            65% (HR 0.35 [95% CI, 0.25-<br \/>0.49], P&lt;0.0001)\n          <\/p>\n<\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            27% (HR 0.73 [95% CI,<br \/>0.55-0.95]\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          Placebo\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"12\">\n<p class=\"bwcellpmargin\">\n            *PSR = Platinum-sensitive recurrent ovarian cancer\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"12\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The most-common adverse events reported in 20% or more of patients<br \/>\n      across the SOLO-2 trial in the LYNPARZA arm were anaemia (44%), nausea<br \/>\n      (76%), vomiting (37%), diarrhoea (33%), fatigue\/asthenia (66%),<br \/>\n      decreased appetite (22%), headache (25%), and dysgeusia (27%). The<br \/>\n      most-common Grade 3 or 4 adverse events were anaemia (20%), nausea<br \/>\n      (2.6%), vomiting (2.6%), diarrhoea (1.0%), fatigue\/asthenia (4.1%), and<br \/>\n      headache (0.5%). Discontinuation of LYNPARZA resulting from adverse<br \/>\n      events was seen in 11% of patients. Dose interruptions of LYNPARZA due<br \/>\n      to an adverse reaction of any grade was 45%. Dose reductions of LYNPARZA<br \/>\n      due to an adverse reaction was 25%.\n    <\/p>\n<p>\n      The most-common adverse events reported in 20% or more of patients<br \/>\n      across the Study 19 trial in the LYNPARZA arm were anaemia (23%), nausea<br \/>\n      (71%), vomiting (35%), diarrhoea (27%), fatigue (including asthenia)<br \/>\n      (63%), decreased appetite (21%), and headache (21%). The most-common<br \/>\n      Grade 3 or 4 adverse events were anaemia (7.4%), nausea (2.2%), vomiting<br \/>\n      (2.2%), diarrhoea (2.2%), and fatigue (including asthenia) (8.8%).<br \/>\n      Discontinuation of LYNPARZA resulting from adverse events was seen in 4%<br \/>\n      of patients. Dose interruptions of LYNPARZA due to an adverse reaction<br \/>\n      of any grade was 25%. Dose reductions of LYNPARZA due to an adverse<br \/>\n      reaction was 15%.\n    <\/p>\n<p>\n      The full data from the SOLO-2 trial can be found in the July 25, 2017<br \/>\n      publication of <i>The Lancet Oncology<\/i>.\n    <\/p>\n<p>\n      LYNPARZA was first approved under the FDA\u2019s Accelerated Approval program<br \/>\n      in December 2014, as a capsule formulation, making it the first poly<br \/>\n      ADP-ribose polymerase (PARP) inhibitor approved. Since then, more than<br \/>\n      3,000 advanced ovarian cancer patients have been treated with LYNPARZA<br \/>\n      capsules in its approved indication.\n    <\/p>\n<p>\n      <b>About SOLO-2<\/b>\n    <\/p>\n<p>\n      SOLO-2 was a Phase III, randomized, double-blinded, multicenter trial<br \/>\n      designed to determine the efficacy of LYNPARZA tablets as a maintenance<br \/>\n      monotherapy compared with placebo, in patients with platinum-sensitive,<br \/>\n      relapsed or recurrent gBRCA-mutated ovarian, fallopian tube and primary<br \/>\n      peritoneal cancer. The trial, conducted in collaboration with the<br \/>\n      European Network for Gynaecological Oncological Trial Groups (ENGOT) and<br \/>\n      Groupe d\u2019Investigateurs National pour l\u2019Etude des Cancers de l\u2019Ovaire et<br \/>\n      du sein (GINECO), randomised 295 patients with documented germline BRCA1<br \/>\n      or BRCA2 mutations who had received at least 2 prior lines of<br \/>\n      platinum-based chemotherapy and were in complete or partial response.<br \/>\n      Eligible patients were randomized to receive 300mg LYNPARZA tablets<br \/>\n      twice daily or placebo tablets twice daily.\n    <\/p>\n<p>\n      <b>About Study 19<\/b>\n    <\/p>\n<p>\n      Study 19 was a Phase II, randomized, double-blinded, placebo-controlled,<br \/>\n      multicenter trial, which evaluated the efficacy and safety of LYNPARZA<br \/>\n      compared with placebo in relapsed, high-grade serous ovarian cancer<br \/>\n      patients, involving 82 sites across 16 countries. Patients received<br \/>\n      LYNPARZA maintenance monotherapy, at a dose of 400mg per day or matching<br \/>\n      placebo. Treatment continued until disease progression if toxicities<br \/>\n      were manageable.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b>\n    <\/p>\n<p>\n      LYNPARZA is an innovative, first-in-class oral poly ADP-ribose<br \/>\n      polymerase (PARP) inhibitor that may exploit tumor DNA damage response<br \/>\n      (DDR) pathway deficiencies to preferentially kill cancer cells. It is<br \/>\n      approved by regulatory authorities in the EU and US for the treatment of<br \/>\n      women with BRCAm ovarian cancer. LYNPARZA tablets are currently being<br \/>\n      tested in combinations in a range of tumor types including breast,<br \/>\n      prostate, and pancreatic cancers.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      On July 27, 2017, AstraZeneca and Merck &amp; Co., Inc. announced a global<br \/>\n      strategic oncology collaboration to co-develop and co-commercialize<br \/>\n      AstraZeneca\u2019s LYNPARZA, the world\u2019s first and leading PARP inhibitor,<br \/>\n      and potential new medicine selumetinib, a MEK inhibitor, for multiple<br \/>\n      cancer types. The collaboration is based on increasing evidence that<br \/>\n      PARP and MEK inhibitors can be combined with PDL-1\/PD-1 inhibitors for a<br \/>\n      range of tumor types. Working together, the companies will jointly<br \/>\n      develop LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Findex.html&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=e3cce83029cbd055ef0057d9fec65754\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=0ac38736898ea0f56fff55f1d50f3b1f\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=a2c16efdfd310a5d0bf5911d1a31ee6a\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=62f76556c5338926503903d27a049b66\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=81c5cd51b8e3151237d2646dfacfc1e2\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=1d304037aa67f063105dc7c15fbeaa9f\" rel=\"nofollow\">YouTube<\/a>&nbsp;and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=f0ab3c845cbbdf1fba6c979e131101a3\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51669441&amp;newsitemid=20170817005960&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=5f1624c368afdf8b12f62d785c829563\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170817005960r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Claire        Mulhearn, 908-740-6444<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>LYNPARZA\u2019s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting Newly-Approved Tablet Formulation Means Improved Patient Convenience AstraZeneca and Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, LYNPARZA (olaparib), as follows: New use of LYNPARZA as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status; New use of LYNPARZA tablets (2 tablets twice daily) as opposed to capsules (8 capsules twice daily); LYNPARZA tablets also now indicated (conversion from the current accelerated approval) for the use in patients with<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745506","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"LYNPARZA\u2019s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting Newly-Approved Tablet Formulation Means Improved Patient Convenience AstraZeneca and Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, LYNPARZA (olaparib), as follows: New use of LYNPARZA as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status; New use of LYNPARZA tablets (2 tablets twice daily) as opposed to capsules (8 capsules twice daily); LYNPARZA tablets also now indicated (conversion from the current accelerated approval) for the use in patients with\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\\\/\",\"name\":\"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-08-17T14:36:00+00:00\",\"dateModified\":\"2025-11-07T06:26:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer - Merck.com","og_description":"LYNPARZA\u2019s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting Newly-Approved Tablet Formulation Means Improved Patient Convenience AstraZeneca and Merck &amp; Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, LYNPARZA (olaparib), as follows: New use of LYNPARZA as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status; New use of LYNPARZA tablets (2 tablets twice daily) as opposed to capsules (8 capsules twice daily); LYNPARZA tablets also now indicated (conversion from the current accelerated approval) for the use in patients with","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:20+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/","name":"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-08-17T14:36:00+00:00","dateModified":"2025-11-07T06:26:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-receives-additional-and-broad-approval-in-the-u-s-for-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"36b9df23-7ec1-4909-9159-14680da058d0","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/LYNPARZA-Receives-Additional-and-Broad-Approval-in-the-US-for-Ovarian-Cancer-2017.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745506\/revisions"}],"predecessor-version":[{"id":3674862,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745506\/revisions\/3674862"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745506"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}